EUROPEAN COMMISSION APPROVES AMGEN’S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
First and Only CD19-Targeted Therapy Approved in Europe for Adults with anti-AChR+ and anti-MuSK+ gMG UPLIZNA Demonstrates Durable Disease Control with Twice-Yearly Dosing* THOUSAND OAKS, Calif., Feb. 12, 2026 /PRNewswire/ — Amgen
